Communiqués StimCell Energetics Inc.

Actions

STME

US15115X2062

Recherche biotechnologique et médicale

Temps Différé OTC Markets 15:30:00 17/09/2026			Varia. 5j.	Varia. 1 janv.
0,2200 ^USD	-10,93 %		-.--%	-45,00 %

09/09	Stimcell Energetics Inc. mandate Stonegate Capital Markets Inc. comme conseiller non exclusif pour ses transactions stratégiques sur les marchés de capitaux	CI
31/08	StimCell Energetics Inc. publie ses résultats pour l'exercice clos le 31 mai 2026	CI

Communiqués

08/09	StimCell Energetics Engages Stonegate Capital Markets as Non-Exclusive Advisor for Strategic Capital Market Transactions	AQ
15/05	Stonegate Initiates Coverage on StimCell Energetics Inc. (STME)	NE
19/03	StimCell Energetics Engages Stonegate Capital Partners for Research Coverage and Institutional Investor Outreach	AQ
02/09/25	StimCell Energetics : Annual Report for Fiscal Year Ending 05-31, 2025 (Form 10-K)	PU
26/03/25	StimCell Energetics Provides Sneak Peek at eBalance Redesign Progress and Announces Shares for Debt Transaction and the Engagement of Independent Investor Relations Consultant	AQ
05/11/24	Cell MedX : StimCell Energetics Inc. (formerly “Cell MedX Corp.”) Announces Major Corporate Updates and Rebranding Form 8 K	PU
19/03/24	Cell MedX Corp. Closes Private Placement Financing	NE
28/02/24	Cell MedX Corp. Announces Resignation of Director	NE
26/02/24	Cell MedX Corp. Appoints Dr. George Adams as Chairman of the Board	NE
19/12/23	Cell MedX Corp. Announces New CEO and Directors and Debt Settlement	NE
27/11/23	Cell MedX Corp. Announces Full Revocation of British Columbia Cease Trade Order	NE
09/11/23	Cell MedX Corp. Appoints Audit Committee and Accepts Resignation of Chief Operating Officer	NE
19/04/23	CELL MEDX CORP. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ
07/04/23	CELL MEDX CORP. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-K)	AQ
19/10/22	Cell MedX Amends Loan Agreements, Provides Update on Financing and Regulatory Compliance	AQ
18/10/22	Cell MedX : Amends Loan Agreements, Provides Update on Financing and Regulatory Compliance - Form 8-K	PU
18/10/22	CELL MEDX CORP. : Entry into a Material Definitive Agreement, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
21/09/22	Cell MedX Corp. - FDA Submission and Corporate Update	AQ
28/06/22	Cell MedX Corp. - Provides Letter to Shareholders from Mr. Dwayne Yaretz, CEO	AQ
28/04/22	Cell MedX Corp. Appoints Mr. Dwayne Yaretz as CEO and Director	AQ
28/04/22	Cell MedX : Appoints Mr. Dwayne Yaretz as CEO and Director - Form 8-K	PU
27/04/22	CELL MEDX CORP. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	AQ
11/04/22	CELL MEDX CORP. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ
25/03/22	Cell MedX Corp. - to Attend The 29th Annual Wellness Show 2022 Held in Vancouver, BC	AQ
12/01/22	CELL MEDX CORP. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ